Ftse Mib
35.390,52
-0,06%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.858,63
2,48%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kintara Therapeutics Inc (KTRA) Kintara Therapeutics Inc (KTRA) Notizie

KTRA

Kintara Therapeutics (KTRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTRA
DataOraFonteTitoloSimboloCompagnia
17/05/202422:10Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTRAKintara Therapeutics Inc
17/05/202422:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422:55Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422:45PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial ResultsNASDAQ:KTRAKintara Therapeutics Inc
14/05/202422:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTRAKintara Therapeutics Inc
13/05/202422:06Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
05/04/202419:09PR Newswire (US)Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmNASDAQ:KTRAKintara Therapeutics Inc
03/04/202413:00PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger AgreementNASDAQ:KTRAKintara Therapeutics Inc
27/03/202414:00PR Newswire (US)Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on PembrolizumabNASDAQ:KTRAKintara Therapeutics Inc
14/02/202422:07PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
12/02/202415:00PR Newswire (US)Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast CancerNASDAQ:KTRAKintara Therapeutics Inc
18/12/202322:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KTRAKintara Therapeutics Inc
07/12/202315:00PR Newswire (US)Kintara Therapeutics Announces Review of Strategic AlternativesNASDAQ:KTRAKintara Therapeutics Inc
05/12/202315:00PR Newswire (US)Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing RequirementNASDAQ:KTRAKintara Therapeutics Inc
13/11/202322:10PR Newswire (US)Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:KTRAKintara Therapeutics Inc
31/10/202313:00PR Newswire (US)Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE StudyNASDAQ:KTRAKintara Therapeutics Inc
27/10/202322:05Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
04/10/202322:35Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:KTRAKintara Therapeutics Inc
21/09/202315:35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:KTRAKintara Therapeutics Inc
18/09/202322:25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KTRAKintara Therapeutics Inc
02/09/202300:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTRAKintara Therapeutics Inc
01/09/202322:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTRAKintara Therapeutics Inc
15/06/202321:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KTRAKintara Therapeutics Inc
11/05/202314:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202322:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:KTRAKintara Therapeutics Inc
31/03/202322:15Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KTRAKintara Therapeutics Inc
13/02/202322:30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KTRAKintara Therapeutics Inc
30/12/202222:58ValueWalkIs Kintara Therapeutics A Hidden Gem?NASDAQ:KTRAKintara Therapeutics Inc
28/11/202218:42TipRanksKintara Therapeutics Shares (NASDAQ: KTRA) Surge after Receiving Fast Track DesignationNASDAQ:KTRAKintara Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KTRA

La tua Cronologia

ASX
CM8O
Crowd Media
LSE
0A61
Discovery Silver
DOWI
W2BSC
DJ Global exUS Basic Mat...
BIT
F17422
Vontobel Financial Produ...
LSE
ALQD
X$ Asia Xjpcorp
UPBT
MATICBTC
Polygon
BIT
C00113
Commerzbank
BIT
UC045S
Unicredit Bank
BIT
F15399
Vontobel Financial Produ...
BIT
UC2PHX
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network